George Yu
Geen lopende functies
Loopbaan van George Yu
Eerdere bekende functies van George Yu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MEDISUN PRECISION MEDICINE LTD. | Directeur/Bestuurslid | 29-08-2012 | 19-01-2017 |
| Algemeen Directeur | 29-08-2012 | 19-01-2017 | |
| Financieel Directeur/CFO | 29-08-2012 | 19-01-2017 | |
| Oprichter | 29-08-2012 | 19-01-2017 | |
| President | 29-08-2012 | 19-01-2017 | |
SinoBiomed, Inc.
 SinoBiomed, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are researching, developing, testing and evaluating proposed new pharmaceutical products. Other activity includes developing cosmetic products. | Directeur/Bestuurslid | 04-02-2011 | 04-08-2011 |
| Financieel Directeur/CFO | 16-06-2011 | 04-08-2011 | |
| President | 03-09-2010 | 16-06-2011 | |
| LOGIQ, INC. | Directeur/Bestuurslid | 01-03-2012 | - |
| Financieel Directeur/CFO | 01-03-2012 | 20-12-2012 | |
| President | 01-03-2012 | 20-12-2012 |
Opleiding van George Yu
| Eberhard Karls Universität Tübingen | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| China | 2 |
| Duitsland | 2 |
Operationeel
| Director/Board Member | 3 |
| Director of Finance/CFO | 3 |
| President | 3 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
| Technology Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LOGIQ, INC. | Technology Services |
| Bedrijven in privébezit | 2 |
|---|---|
SinoBiomed, Inc.
SinoBiomed, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are researching, developing, testing and evaluating proposed new pharmaceutical products. Other activity includes developing cosmetic products. | Health Technology |
Medisun Precision Medicine Ltd.
 Medisun Precision Medicine Ltd. BiotechnologyHealth Technology Medisun Precision Medicine Ltd. is a biotechnology company, which focuses on developing novel neurological therapies to be directly delivered into specific regions of the brain. It portfolio includes ACX-31 program to deliver two chemotherapy drugs, temozolomide in combination with BCNU, locally to brain tumor sites. The company was founded on August 29, 2012 and is headquartered in Majuro, Marshall Islands. | Health Technology |
